Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Ionis Pharmaceuticals, Inc.”

202 pharma patents match "Ionis Pharmaceuticals, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 202
Index total 30,257
Page 7 / 9

Quick answer

This filtered view shows 202 pharmaceutical patents matching "Ionis Pharmaceuticals, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

202 results for “Ionis Pharmaceuticals, Inc.” · 30,257 patents in full index Clear search

  1. US 9957504

    Compositions and methods for modulating apolipoprotein (a) expression

    Ionis Pharmaceuticals, Inc. · Granted May 1, 2018 · Expires Apr 26, 2038

    granted
  2. US 9957292

    Compositions and methods for modulating angiopoietin-like 3 expression

    Ionis Pharmaceuticals, Inc. · Granted May 1, 2018 · Expires Apr 26, 2038

    granted
  3. US 9943539

    2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations

    Ionis Pharmaceuticals, Inc. · Granted Apr 17, 2018 · Expires Apr 12, 2038

    granted
  4. US 9943604

    Targeted therapeutic nucleosides and their use

    Ionis Pharmaceuticals, Inc. · Granted Apr 17, 2018 · Expires Apr 12, 2038

    granted
  5. US 9943538

    2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations

    Ionis Pharmaceuticals, Inc. · Granted Apr 17, 2018 · Expires Apr 12, 2038

    granted
  6. US 9932581

    Compositions and methods for modulating apolipoprotein C-III expression

    Ionis Pharmaceuticals, Inc. · Granted Apr 3, 2018 · Expires Mar 29, 2038

    granted
  7. US 9932580

    Compositions and methods for modulating HBV expression

    Ionis Pharmaceuticals, Inc. · Granted Apr 3, 2018 · Expires Mar 29, 2038

    granted
  8. US 9920321

    Compositions and their uses directed to huntingtin

    Ionis Pharmaceuticals, Inc. · Granted Mar 20, 2018 · Expires Mar 15, 2038

    granted
  9. US 9909124

    Compounds and methods for modulating apolipoprotein C-III expression for improving a diabetic profile

    Ionis Pharmaceuticals, Inc. · Granted Mar 6, 2018 · Expires Mar 1, 2038

    granted
  10. US 9885047

    Modulation of TMPRSS6 expression

    Ionis Pharmaceuticals, Inc. · Granted Feb 6, 2018 · Expires Feb 1, 2038

    granted
  11. US 9885045

    Methods and compositions for modulating apolipoprotein (a) expression

    Ionis Pharmaceuticals, Inc. · Granted Feb 6, 2018 · Expires Feb 1, 2038

    granted
  12. US 9884072

    Methods and compositions for modulating apolipoprotein (a) expression

    Ionis Pharmaceuticals, Inc. · Granted Feb 6, 2018 · Expires Feb 1, 2038

    granted
  13. US 9873876

    Cancer treatment

    Ionis Pharmaceuticals, Inc. · Granted Jan 23, 2018 · Expires Jan 18, 2038

    granted
  14. US 9827263

    2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations

    Ionis Pharmaceuticals, Inc. · Granted Nov 28, 2017 · Expires Nov 23, 2037

    granted
  15. US 9816092

    Modulation of transthyretin expression

    Ionis Pharmaceuticals, Inc. · Granted Nov 14, 2017 · Expires Nov 9, 2037

    granted
  16. US 9796976

    Methods and compositions for modulating alpha-1 antitrypsin expression

    Ionis Pharmaceuticals, Inc. · Granted Oct 24, 2017 · Expires Oct 19, 2037

    granted
  17. US 9765338

    Modulation of dystrophia myotonica-protein kinase (DMPK) expression

    Ionis Pharmaceuticals, Inc. · Granted Sep 19, 2017 · Expires Sep 14, 2037

    granted
  18. US 9725722

    Modulation of TMPRSS6 expression

    Ionis Pharmaceuticals, Inc. · Granted Aug 8, 2017 · Expires Aug 3, 2037

    granted
  19. US 9714421

    Compositions and methods

    Ionis Pharmaceuticals, Inc. · Granted Jul 25, 2017 · Expires Jul 20, 2037

    granted
  20. US 9708610

    Compositions comprising alternating 2′-modified nucleosides for use in gene modulation

    Ionis Pharmaceuticals, Inc. · Granted Jul 18, 2017 · Expires Jul 13, 2037

    granted
  21. US 9695475

    Competitive modulation of microRNAs

    Ionis Pharmaceuticals, Inc. · Granted Jul 4, 2017 · Expires Jun 29, 2037

    granted
  22. US 9688987

    Antisense oligonucleotides directed against connective tissue growth factor and uses thereof

    Ionis Pharmaceuticals, Inc. · Granted Jun 27, 2017 · Expires Jun 22, 2037

    granted
  23. US 9683235

    Compositions for modulating Tau expression

    Ionis Pharmaceuticals, Inc. · Granted Jun 20, 2017 · Expires Jun 15, 2037

    granted
  24. US 9683236

    Modulation of huntingtin expression

    Ionis Pharmaceuticals, Inc. · Granted Jun 20, 2017 · Expires Jun 15, 2037

    granted